UK Approves First Omicron-Targeted Treatment as Vaccine Stockpiles Grow
British health authorities have approved sotrovimab (brand name Xevudy), a monoclonal antibody drug developed by GSK and Vir Biotechnology, claiming it could remain effective against the fast-spreading Omicron variant. The treatment reduced hospitalization/death risk by 79% in trials for high-risk patients with mild-to-moderate COVID-19.
Science Meets Strategy
While UK regulators caution it's 'too early to confirm Omicron impact,' developers say lab tests show the drug neutralizes all known variants. \"We designed it anticipating viral mutations,\" said Vir CEO George Scangos – a potential game-changer for immunocompromised individuals.
Vaccine Boost Sparks Equity Debate
In parallel, the UK secured 114 million additional COVID-19 vaccine doses (60M Moderna, 54M Pfizer) for 2022-23. Health Secretary Sajid Javid called it \"future-proofing\" Britain's jab campaign . But WHO officials criticized wealthy nations for stockpiling: \"Many countries still can't vaccinate their most vulnerable,\" said WHO's Mike Ryan .
As Omicron cases hit 32 across England/Scotland this week, global health leaders urge balancing national preparedness with vaccine equity.
The treatment reduced hospitalization/death risk by 79% in trials for high-risk patients with mild-to-moderate COVID-19.
Science Meets Strategy
Vaccine Boost Sparks Equity Debate
. But WHO officials criticized wealthy nations for stockpiling: \"Many countries still can't vaccinate their most vulnerable,\" said WHO's Mike Ryan 
.
